

**Exhibit 1**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(In thousands of US dollars)

	As of December 31, 2014	As of June 30, 2015
	US\$ (Note 1)	US\$ (unaudited)
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents (Note 2)	276,598	284,194
Restricted cash (Note 3)	7,422	10,683
Restricted investments (Note 4)	-	244,128
Short-term investments (Note 2)	816,394	529,544
Accounts receivable, net	222,522	188,485
Inventories	150,642	172,785
Value added tax receivables	3,432	11,398
Other receivables and current assets	23,316	105,184
Prepayments and deposits	16,481	18,976
Deferred tax assets, net	14,802	17,957
Total current assets	1,531,609	1,583,334
Restricted cash, non-current (Note 3)	5,061	2,784
Other assets	9,666	9,605
Accounts receivables, net, non-current	3,350	2,566
Advances for purchase of plant and equipment	21,840	19,725
Property, plant and equipment, net	412,733	438,624
Land use rights, net	59,057	58,414
Intangible assets, net	175,451	165,612
Goodwill	254,435	254,510
Total assets	2,473,202	2,535,174
<b>LIABILITIES AND EQUITY</b>		
Current liabilities:		
Short-term bank loans	59,625	129,115
Notes payable	9,234	8,211
Accounts payable	93,523	90,720
Advances from customers	31,396	52,266
Salaries payable	114,583	79,924
Other payables and current liabilities	168,139	168,825
Purchase consideration payable	17,173	11,592
Income taxes payable	20,415	23,405
Other taxes payable	10,342	6,354
Total current liabilities	524,430	570,412
Long-term bank loans	197,585	168,000
Other long-term liabilities	10,670	11,280
Deferred tax liabilities, net	69,233	74,574
Total liabilities	801,918	824,266
Mindray shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	453,564	462,765
Retained earnings	1,000,257	1,026,495
Accumulated other comprehensive income	144,120	145,158
Treasury stock at cost	-	-
Total Mindray shareholders' equity	1,597,956	1,634,433
Non-controlling interests	73,328	76,475
Total equity	1,671,284	1,710,908
Total liabilities and equity	2,473,202	2,535,174

(1) Financial information is extracted from the audited financial statements included in the Company's 2014 annual report on Form 20-F.

(2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of \$189,000 and \$nil as of December 31, 2014 and June 30, 2015, respectively in relation to the drawings of certain bank loans.

(3) Restricted cash are mainly those purchase consideration in connection with our acquisitions being held on escrow accounts.

(4) Restricted investments are those investments in Chinese Renminbi denominated financial products placed with bank which are restricted as to withdrawal

or usage according to new terms imposed on certain bank loans during the quarter ended March 31, 2015.

**Exhibit 2**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(In thousands of US dollars, except share and per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2014	2015	2014	2015
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Net revenues				
- China	152,469	153,864	268,297	275,821
- International	181,983	182,953	330,926	333,460
Net revenues	334,452	336,817	599,223	609,281
Cost of revenues	(145,237)	(152,584)	(263,988)	(276,213)
Gross profit	189,215	184,233	335,235	333,068
Selling expenses	(63,471)	(63,860)	(118,267)	(120,318)
General and administrative expenses	(27,578)	(33,993)	(57,391)	(60,946)
Research and development expenses	(33,724)	(36,403)	(63,867)	(70,889)
Income from operations	64,442	49,977	95,710	80,915
Other (expenses) income, net	(215)	908	1,594	1,793
Interest income	7,678	3,048	18,457	14,330
Interest expense	(1,291)	(1,108)	(3,686)	(2,093)
Income before income taxes and non-controlling interests	70,614	52,825	112,075	94,945
Income tax provision	(9,448)	(10,157)	(13,948)	(18,463)
Net income	61,166	42,668	98,127	76,482
Less: Net income attributable to non-controlling interests	(1,548)	(1,507)	(2,871)	(3,147)
Net income attributable to Mindray shareholders	59,618	41,161	95,256	73,335
Basic earnings per share	0.51	0.35	0.81	0.62
Diluted earnings per share	0.50	0.35	0.81	0.62
Shares used in the computation of:				
Basic earnings per share	116,974,009	117,831,719	116,914,653	117,823,198
Diluted earnings per share	118,132,930	118,700,403	118,313,540	118,809,042

**Exhibit 3**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands of US dollars)

	Three months ended June 30,		Six months ended June 30,	
	2014	2015	2014	2015
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
<b>Cash flow from operating activities:</b>				
Net income	61,166	42,668	98,127	76,482
Adjustments to reconcile net income to net cash provided by operating activities	20,833	31,524	48,697	55,382
Changes in assets and liabilities, net of effects of acquisitions	2,600	(12,107)	(42,559)	(32,787)
<b>Net cash provided by operating activities</b>	<b>84,599</b>	<b>62,085</b>	<b>104,265</b>	<b>99,077</b>
<b>Cash flow from investing activities:</b>				
Acquisition cost of subsidiaries, net of cash received	(6,009)	(3,071)	(8,215)	(5,578)
Capital expenditures	(23,176)	(20,316)	(51,051)	(51,096)
Decrease (Increase) in restricted cash and restricted investments	4,941	-	(1,514)	(53,114)
Proceeds from sale of short-term investments	374,551	142,794	616,515	152,571
Increase in short-term investments and changes in other investing activities	(328,773)	(115,798)	(341,738)	(132,181)
<b>Net cash provided by (used in) investing activities</b>	<b>21,534</b>	<b>3,609</b>	<b>213,997</b>	<b>(89,398)</b>
<b>Cash flow from financing activities:</b>				
Repayment of bank loans	(160,000)	(4,375)	(210,000)	(4,375)
Proceeds from bank loans, net of costs	-	-	-	47,712
Dividend paid	-	-	(58,711)	(47,097)
Proceeds from exercise of options	669	242	1,014	1,857
Repurchase of ordinary American depository shares	(51)	-	(68,080)	-
Cash paid to acquire a non-controlling interest	(4,286)	-	(4,731)	-
Cash contribution from a non-controlling interest	-	-	239	-
<b>Net cash used in financing activities</b>	<b>(163,668)</b>	<b>(4,133)</b>	<b>(340,269)</b>	<b>(1,903)</b>
<b>Net (decrease) increase in cash and cash equivalents</b>	<b>(57,535)</b>	<b>61,561</b>	<b>(22,007)</b>	<b>7,776</b>
Cash and cash equivalents, beginning of period	419,820	221,699	385,224	276,598
Effect of exchange rate changes on cash and cash equivalents	26	934	(906)	(180)
<b>Cash and cash equivalents, end of period</b>	<b>362,311</b>	<b>284,194</b>	<b>362,311</b>	<b>284,194</b>

**Exhibit 4**
**MINDRAY MEDICAL INTERNATIONAL LIMITED**
**RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES**

(In thousands of US dollars, except share and per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2014	2015	2014	2015
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	US\$	US\$	US\$	US\$
<b>Non-GAAP net income attributable to Mindray shareholders</b>	66,219	49,496	112,273	88,953
Non-GAAP net margin	19.8%	14.7%	18.7%	14.6%
Amortization of acquired intangible assets	(3,438)	(3,314)	(6,885)	(6,692)
Deferred tax impact related to acquired intangible assets	604	617	1,219	1,235
Dispute related legal fees, net of related tax impact	-	(1,900)	-	(2,819)
Share-based compensation	(3,767)	(3,738)	(11,351)	(7,342)
GAAP net income attributable to Mindray shareholders	59,618	41,161	95,256	73,335
GAAP net margin	17.8%	12.2%	15.9%	12.0%
Non-GAAP basic earnings per share	0.57	0.42	0.96	0.75
Non-GAAP diluted earnings per share	0.56	0.42	0.95	0.75
GAAP basic earnings per share	0.51	0.35	0.81	0.62
GAAP diluted earnings per share	0.50	0.35	0.81	0.62
Shares used in computation of:				
Basic earnings per share	116,974,009	117,831,719	116,914,653	117,823,198
Diluted earnings per share	118,132,930	118,700,403	118,313,540	118,809,042
<b>Non-GAAP operating income</b>	71,647	59,264	113,946	98,266
Non-GAAP operating margin	21.4%	17.6%	19.0%	16.1%
Amortization of acquired intangible assets	(3,438)	(3,314)	(6,885)	(6,692)
Dispute related legal fees	-	(2,235)	-	(3,317)
Share-based compensation	(3,767)	(3,738)	(11,351)	(7,342)
GAAP operating income	64,442	49,977	95,710	80,915
GAAP operating margin	19.3%	14.8%	16.0%	13.3%
<b>Non-GAAP gross profit</b>	191,414	186,050	339,538	336,969
Non-GAAP gross margin	57.2%	55.2%	56.7%	55.3%
Amortization of acquired intangible assets	(1,937)	(1,724)	(3,868)	(3,514)
Share-based compensation	(262)	(93)	(435)	(387)
GAAP gross profit	189,215	184,233	335,235	333,068
GAAP gross margin	56.6%	54.7%	55.9%	54.7%
<b>Non-GAAP selling expenses</b>	(60,585)	(60,908)	(112,759)	(114,467)
Non-GAAP as % of total net revenues	18.1%	18.1%	18.8%	18.8%
Amortization of acquired intangible assets	(1,501)	(1,590)	(3,017)	(3,178)
Share-based compensation	(1,385)	(1,362)	(2,491)	(2,673)
GAAP selling expenses	(63,471)	(63,860)	(118,267)	(120,318)
GAAP as % of total net revenues	19.0%	19.0%	19.7%	19.7%
<b>Non-GAAP general and administrative expenses</b>	(26,844)	(30,761)	(51,406)	(55,858)
Non-GAAP as % of total net revenues	8.0%	9.1%	8.6%	9.2%
Dispute related legal fees	-	(2,235)	-	(3,317)
Share-based compensation	(734)	(997)	(5,985)	(1,771)
GAAP general and administrative expenses	(27,578)	(33,993)	(57,391)	(60,946)
GAAP as % of total net revenues	8.2%	10.1%	9.6%	10.0%
<b>Non-GAAP research and development expenses</b>	(32,338)	(35,117)	(61,427)	(68,378)
Non-GAAP as % of total net revenues	9.7%	10.4%	10.3%	11.2%
Share-based compensation	(1,386)	(1,286)	(2,440)	(2,511)
GAAP research and development expenses	(33,724)	(36,403)	(63,867)	(70,889)
GAAP as % of total net revenues	10.1%	10.8%	10.7%	11.6%

**Exhibit 5****MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION****(In thousands of US dollars)**

	Three months ended June 30,		Six months ended June 30,	
	2014	2015	2014	2015
	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)
GAAP net income attributable to the Company	59,618	41,161	95,256	73,335
Interest income	(7,678)	(3,048)	(18,457)	(14,330)
Interest expense	1,291	1,108	3,686	2,093
Income tax provision	9,448	10,157	13,948	18,463
Earnings before interest and taxes ("EBIT")	62,679	49,378	94,433	79,561
Depreciation	8,704	9,949	17,332	19,771
Amortization	5,567	5,452	11,146	10,970
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	76,950	64,779	122,911	110,302